Partnered with

DKFZ - German Cancer Research Center

The German Cancer Research Center (DKFZ) is the largest biomedical research institute in Germany and a member of the Helmholtz Association of National Research Centers. In over 90 divisions and research groups, more than 2,700 employees, of which more than 1,200 are scientists, are investigating the mechanisms of cancer, are identifying cancer risk factors and are trying to find strategies to prevent people from getting cancer. They are developing novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful.

 

German Pavilion at BIO 2017 in San Diego, USA

Genewerk ist at BIO 2017 one of 39 German companies that will present their work from June 19. to 22., 2017 at German Pavilion in San Diego, USA.

GeneWerk GmbH
Booth number: 4607-7

GenoSafe

GenoSafe and GeneWerk announced a collaborative framework agreement. Both companies will work together within the field of development of chemical, biotechnological and biological products. The aim is to complement the expertise of the partner to optimize response to client requests for expert evaluations.n.

 

Individualized Genotoxicity (InGeTox) Assay - A Cross-Functional Team Initiative

European Commission Horizon 2020 - SCIDNET

SCIDNET is a European Commission Horizon 2020 -funded project which started in January 2016. During 4 years the project aims to develop gene therapy for Severe Combined Immuno Deficiencies (SCID) to a medicinal product that can cure affected children. SCID result in severe abnormalities of the immune system, and prevent children to fight against infections. This leads to death in the first year of life if no effective treatment is given.

Together with in total 12 partners across Europe GeneWerk is part of this challenging project. As workpackage leader of WP6 “Genomic integration analysis for SCID gene therapy” our aim is to develop new strategies for demonstrating and monitoring the safety and efficiency of the gene therapy regimens. The initiative lead by Professor Bobby Gaspar (UCL ICH/GOSH) benefits from the excellent expertise of all partners and the funding from the European Commission and we all hope that it will result in a safe treatment for all affected patients.